Remodulin and Pentoxifylline drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Remodulin (treprostinil sodium) and Pentoxifylline (pentoxifylline). Common drug interactions include hypersensitivity among females and device failure among males.

The phase IV clinical study analyzes what interactions people have when they take Remodulin and Pentoxifylline. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,843 Remodulin users. Check the latest studies of Remodulin.

What is Pentoxifylline?

Pentoxifylline has active ingredients of pentoxifylline. eHealthMe is studying from 5,997 Pentoxifylline users. Check the latest studies of Pentoxifylline.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

14 people who take Remodulin and Pentoxifylline together, and have interactions are studied.

Remodulin and Pentoxifylline drug interactions.

What are the common drug interactions of Remodulin and Pentoxifylline, by gender? *:

female:

Hypersensitivity
Immune system disorder
Secretion discharge
Sinusitis (inflammation of sinus)
Vomiting
Breast swelling
Cerebral haemorrhage (bleeding within the brain)
Fall
Head injury
Loss of consciousness

male:

Device failure
Scleroderma (hard skin)
Encephalopathy (functioning of the brain is affected by some agent or condition)
Malignant atrophic papulosis (an extremely rare vascular weakness that affects the lining of the medium and small veins and arteries)
Nervous system disorder (a general class of medical conditions affecting the nervous system)

What are the common drug interactions of Remodulin and Pentoxifylline, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Encephalopathy (functioning of the brain is affected by some agent or condition)
Malignant atrophic papulosis (an extremely rare vascular weakness that affects the lining of the medium and small veins and arteries)
Nervous system disorder (a general class of medical conditions affecting the nervous system)

20-29:

n/a

30-39:

Catheter related infection
Stenotrophomonas sepsis (blood infection by stenotrophomonas)

40-49:

n/a

50-59:

Influenza
Weight decreased
Pneumonia
Cerebral haemorrhage (bleeding within the brain)
Fall
Head injury
Loss of consciousness
Pain
Hypervolaemia (abnormally increased volume of blood)

60+:

Device failure
Scleroderma (hard skin)
Peripheral swelling
Pneumonia
Respiratory distress (difficulty in breathing)
Secretion discharge
Vomiting
Chills (felling of cold)
Dizziness
Dyspnoea (difficult or laboured respiration)

What are the existing conditions these people have? *

Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 7.14%
Portopulmonary Hypertension (coexistence of portal and pulmonary hypertension): 1 person, 7.14%
Malignant Atrophic Papulosis (an extremely rare vascular weakness that affects the lining of the medium and small veins and arteries): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Remodulin and Pentoxifylline?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously